{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:20:21Z","timestamp":1793424021234,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007658","name":"Baxter Healthcare Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007658","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008207","name":"AstraZeneca Canada Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008207","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020141","name":"Akebia Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014941","name":"Cytokinetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["175095"],"award-info":[{"award-number":["175095"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Basic to Translational Science"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jacbts.2021.10.018","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T15:31:22Z","timestamp":1646235082000},"page":"504-517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["Optimizing Foundational Therapies in Patients With HFrEF"],"prefix":"10.1016","volume":"7","author":[{"given":"Abhinav","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Connelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4544-4057","authenticated-orcid":false,"given":"Elizabeth","family":"Swiggum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Zieroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jacbts.2021.10.018_bib1","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics\u20142021 update: a report from the American Heart Association","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacbts.2021.10.018_bib2","article-title":"Trends in noncardiovascular comorbidities among patients hospitalized for heart failure","volume":"11","author":"Sharma","year":"2018","journal-title":"Circ Hear Fail"},{"issue":"6","key":"10.1016\/j.jacbts.2021.10.018_bib3","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","volume":"77","author":"Maddox","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacbts.2021.10.018_bib4","first-page":"531","article-title":"CCS\/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction","volume":"37","author":"McDonald","year":"2021","journal-title":"Can J Cardiol"},{"issue":"10244","key":"10.1016\/j.jacbts.2021.10.018_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jacbts.2021.10.018_bib6","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1161\/CIRCULATIONAHA.119.041022","article-title":"Impact of regulatory guidance on evaluating cardiovascular risk of new glucose-lowering therapies to treat type 2 diabetes mellitus: lessons learned and future directions","volume":"141","author":"Sharma","year":"2020","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.jacbts.2021.10.018_bib7","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jacc.2018.06.040","article-title":"Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC State-of-the-Art Review","volume":"72","author":"Zelniker","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jacbts.2021.10.018_bib8","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.jacbts.2021.10.018_bib9","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.jacbts.2021.10.018_bib10","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jacbts.2021.10.018_bib11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin\u2013neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jacbts.2021.10.018_bib12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF Registry","volume":"72","author":"Greene","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacbts.2021.10.018_bib13","first-page":"469","article-title":"Contemporary treatment patterns and clinical outcomes of comorbid diabetes mellitus and HFrEF: the CHAMP-HF Registry","volume":"8","author":"Vaduganathan","year":"2020","journal-title":"J\u00a0Am Coll Cardiol HF"},{"issue":"19","key":"10.1016\/j.jacbts.2021.10.018_bib14","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacbts.2021.10.018_bib15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ehf2.12528","article-title":"Eligibility of sodium\u2013glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure","volume":"7","author":"Sharma","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"3","key":"10.1016\/j.jacbts.2021.10.018_bib16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jamacardio.2020.5864","article-title":"Applicability of US Food and Drug Administration labeling for dapagliflozin to patients with heart failure with reduced ejection fraction in US clinical practice: the Get with the Guidelines-Heart Failure (GWTG-HF) Registry","volume":"6","author":"Vaduganathan","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"10","key":"10.1016\/j.jacbts.2021.10.018_bib17","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/ejhf.900","article-title":"Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF","volume":"19","author":"Ferreira","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.jacbts.2021.10.018_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.6139","article-title":"Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US","volume":"4","author":"Eberly","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"10266","key":"10.1016\/j.jacbts.2021.10.018_bib19","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.jacbts.2021.10.018_bib20","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.jacbts.2021.10.018_bib21","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/ejhf.2271","article-title":"Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)","volume":"23","author":"Savarese","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.jacbts.2021.10.018_bib22","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/ejhf.2149","article-title":"Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction","volume":"23","author":"Packer","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10.1016\/j.jacbts.2021.10.018_bib23","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/HCO.0000000000000892","article-title":"Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit","volume":"36","author":"Sharma","year":"2021","journal-title":"Curr Opin Cardiol"},{"issue":"16","key":"10.1016\/j.jacbts.2021.10.018_bib24","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.jacc.2013.05.020","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: Executive summary: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jacbts.2021.10.018_bib25","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ejhf.1531","article-title":"Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart\u00a0Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovic","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10.1016\/j.jacbts.2021.10.018_bib26","first-page":"1342","article-title":"2017 Comprehensive update of the Canadian Cardiovascular Society Guidelines for the Management of Heart\u00a0Failure","volume":"33","author":"Ezekowitz","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacbts.2021.10.018_bib27","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIRCULATIONAHA.120.052926","article-title":"How should we sequence the treatments for heart failure and a reduced ejection fraction?: A redefinition of evidence-based medicine","author":"McMurray","year":"2021","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.jacbts.2021.10.018_bib28","doi-asserted-by":"crossref","first-page":"e1008","DOI":"10.1016\/S2214-109X(18)30306-1","article-title":"Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study","volume":"6","author":"Tay","year":"2018","journal-title":"Lancet Glob Heal"},{"issue":"11","key":"10.1016\/j.jacbts.2021.10.018_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/CIRCHEARTFAILURE.117.004478","article-title":"Waiting period before implantable cardioverter-defibrillator implantation in newly diagnosed heart failure with reduced ejection fraction: a window of opportunity","volume":"10","author":"DeFilippis","year":"2017","journal-title":"Circ Heart Fail"},{"issue":"5","key":"10.1016\/j.jacbts.2021.10.018_bib30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamacardio.2020.7585","article-title":"Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction","volume":"6","author":"Berg","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"5","key":"10.1016\/j.jacbts.2021.10.018_bib31","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jamacardio.2020.7596","article-title":"Expediting the benefits of sodium-glucose cotransporter-2 inhibitors for heart failure\u2014there is no time for delay","volume":"6","author":"Fonarow","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"23","key":"10.1016\/j.jacbts.2021.10.018_bib33","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure","volume":"316","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jacbts.2021.10.018_bib34","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ejhf.1351","article-title":"Medication dosing for heart failure with reduced ejection fraction\u2014opportunities and challenges","volume":"21","author":"Marti","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"25","key":"10.1016\/j.jacbts.2021.10.018_bib35","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1093\/eurheartj\/ehaa183","article-title":"Effects of dapagliflozin in DAPA-HF according to background heart failure therapy","volume":"41","author":"Docherty","year":"2020","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.jacbts.2021.10.018_bib36","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003212","article-title":"Effects of sacubitril\/valsartan in the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart\u00a0Failure) according to background therapy","volume":"9","author":"Okumura","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"4","key":"10.1016\/j.jacbts.2021.10.018_bib37","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/CIRCHEARTFAILURE.112.000173","article-title":"Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy analysis of the EMPHASIS-HF study","volume":"6","author":"Krum","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"25","key":"10.1016\/j.jacbts.2021.10.018_bib38","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1093\/eurheartj\/ehaa344","article-title":"Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care","volume":"41","author":"Packer","year":"2020","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.jacbts.2021.10.018_bib39","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1161\/CIRCULATIONAHA.105.582320","article-title":"Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence","volume":"112","author":"Willenheimer","year":"2005","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.jacbts.2021.10.018_bib40","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.jacbts.2021.10.018_bib41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"SOLVD Investigators","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2021.10.018_bib42","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"9169","key":"10.1016\/j.jacbts.2021.10.018_bib43","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart\u00a0Failure (MERIT-HF)","volume":"353","author":"Hjalmarson","year":"1999","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jacbts.2021.10.018_bib44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jacbts.2021.10.018_bib45","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.amjcard.2018.05.038","article-title":"Effect on mortality of higher versus lower \u03b2-blocker (metoprolol succinate or carvedilol) dose in patients with heart failure","volume":"122","author":"Ajam","year":"2018","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.jacbts.2021.10.018_bib46","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archinte.161.2.165","article-title":"Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial","volume":"161","author":"Massie","year":"2001","journal-title":"Arch Intern Med"},{"issue":"9704","key":"10.1016\/j.jacbts.2021.10.018_bib47","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of High-Dose Versus Low-Dose Losartan on Clinical Outcomes in Patients With Heart\u00a0Failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jacbts.2021.10.018_bib48","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/ejhf.2255","article-title":"Dosing of losartan in men versus women with heart failure with reduced ejection fraction","volume":"23","author":"Ferreira","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.jacbts.2021.10.018_bib49","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/ehjcvp\/pvw016","article-title":"Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives","volume":"3","author":"Pitt","year":"2017","journal-title":"Eur Hear J Cardiovasc Pharmacother"},{"issue":"3","key":"10.1016\/j.jacbts.2021.10.018_bib50","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/ejhf.1400","article-title":"Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial","volume":"21","author":"Ferreira","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10.1016\/j.jacbts.2021.10.018_bib51","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/ejhf.2259","article-title":"Effect of sacubitril\/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial","volume":"23","author":"Bhatt","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10.1016\/j.jacbts.2021.10.018_bib52","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","article-title":"Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-Reduced","volume":"77","author":"Ferreira","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacbts.2021.10.018_bib53","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cjco.2020.05.009","article-title":"Cost-effectiveness of earlier transition to angiotensin receptor neprilysin inhibitor in patients with heart failure and reduced ejection fraction","volume":"2","author":"Grant","year":"2020","journal-title":"CJC Open"},{"issue":"12","key":"10.1016\/j.jacbts.2021.10.018_bib54","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1111\/dom.14162","article-title":"Assessing the cost-effectiveness of sodium\u2013glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence","volume":"22","author":"McEwan","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"suppl 3","key":"10.1016\/j.jacbts.2021.10.018_bib55","article-title":"Abstract 15981: cost-effectiveness of dapagliflozin in heart failure with reduced ejection fraction","volume":"142","author":"Isaza","year":"2020","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.jacbts.2021.10.018_bib56","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/jamacardio.2021.1437","article-title":"Cost-effectiveness of dapagliflozin for treatment of patients with heart failure with reduced ejection fraction","volume":"6","author":"Parizo","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"12","key":"10.1016\/j.jacbts.2021.10.018_bib57","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/heartjnl-2016-310661","article-title":"Cost-effectiveness of sacubitril\/valsartan in the treatment of heart failure with reduced ejection fraction","volume":"104","author":"McMurray","year":"2018","journal-title":"Heart"},{"issue":"6","key":"10.1016\/j.jacbts.2021.10.018_bib58","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/ejhf.2206","article-title":"Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart\u00a0Failure Association of the European Society of Cardiology","volume":"23","author":"Rosano","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacbts.2021.10.018_bib59","first-page":"632","article-title":"A\u00a0novel approach to medical management of heart failure with reduced ejection fraction","volume":"37","author":"Miller","year":"2021","journal-title":"Can J Cardiol"},{"issue":"7","key":"10.1016\/j.jacbts.2021.10.018_bib60","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamacardio.2021.0496","article-title":"Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure-optimizing therapy with the need for speed","volume":"6","author":"Greene","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.jacbts.2021.10.018_bib61","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacbts.2021.10.018_bib62","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ahj.2020.10.064","article-title":"Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes\u2014systematic review and meta-analysis of randomized placebo-controlled trials: SGLT2i\u2014Cardiovascular and Kidney Outcomes","volume":"232","author":"Salah","year":"2021","journal-title":"Am Heart J"},{"issue":"6","key":"10.1016\/j.jacbts.2021.10.018_bib63","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1002\/ehf2.13148","article-title":"Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST-WHF in perspective","volume":"7","author":"Verma","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"10254","key":"10.1016\/j.jacbts.2021.10.018_bib64","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jacbts.2021.10.018_bib65","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41569-020-0405-9","article-title":"Benefits of combination pharmacotherapy for HFrEF","volume":"17","author":"Lim","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"10.1016\/j.jacbts.2021.10.018_bib66","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/ejhf.1236","article-title":"Advanced heart failure: a position statement of the Heart\u00a0Failure Association of the European Society of Cardiology","volume":"20","author":"Crespo-Leiro","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacbts.2021.10.018_bib67","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ahj.2019.09.012","article-title":"Care optimization through patient and hospital engagement clinical trial for heart failure: rationale and design of CONNECT-HF","volume":"220","author":"DeVore","year":"2020","journal-title":"Am Heart J"}],"container-title":["JACC: Basic to Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X21003594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X21003594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:25:12Z","timestamp":1762820712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452302X21003594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S2452302X21003594"],"URL":"https:\/\/doi.org\/10.1016\/j.jacbts.2021.10.018","relation":{},"ISSN":["2452-302X"],"issn-type":[{"value":"2452-302X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing Foundational Therapies in Patients With HFrEF","name":"articletitle","label":"Article Title"},{"value":"JACC: Basic to Translational Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacbts.2021.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}